<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429440</url>
  </required_header>
  <id_info>
    <org_study_id>231/2004</org_study_id>
    <nct_id>NCT02429440</nct_id>
  </id_info>
  <brief_title>Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides</brief_title>
  <acronym>UroRCC</acronym>
  <official_title>Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic
      adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage
      colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer
      (RCC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Day 0-365</time_frame>
    <description>Tolerability, as measured by number of Participants with Adverse Events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>60 Months</time_frame>
    <description>All cause Mortality, as measured as length of Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>36 Months</time_frame>
    <description>Progression-free Survival, as measured as time to radiographic progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response</measure>
    <time_frame>Day 0-365</time_frame>
    <description>Immune Response, as as measured by in vitro and in vivo T cell response on day 0 and day 70. In selected cases additional immune response evaluation might be applicable.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Renal Cell Cancer</condition>
  <condition>Advanced Renal Cell Cancer</condition>
  <arm_group>
    <arm_group_label>Study Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intradermal application of peptide vaccine in combination with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intradermal application of peptide vaccine with Montanide ISA-51</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>peptide vaccine</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Study Arm 1</arm_group_label>
    <arm_group_label>Study Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Macrophage Colony Stimulating Factor</intervention_name>
    <description>intradermal</description>
    <arm_group_label>Study Arm 1</arm_group_label>
    <other_name>GM-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montanide ISA-51</intervention_name>
    <description>subcutaneous</description>
    <arm_group_label>Study Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced renal cell carcinoma clinical stage T3 or T4, N0, M0

          -  N+, M0

          -  M1 (after complete metastasectomy)

          -  ECOG performance status 0 or 1

          -  age &gt;18 years

          -  at least 4 weeks since last administration of radiation- or chemotherapy

          -  Serum levels of bilirubin &lt;2 mg/dl, creatinine&lt;2mg/dl

        Exclusion Criteria:

          -  detectable distant metastasis in radiological imaging (M1)

          -  patients unable to consent

          -  severe cardiopulmonary disorder (NYHA &gt;= 3)

          -  presence of secondary malignancy

          -  Immunosuppressive medication (last application of glucocorticoids &gt; 4 weeks)

          -  seizure

          -  pregnancy

          -  simultaneous participation in other active or passive immunisation treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnulf Stenzl, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of TÃ¼bingen, Department of Urology</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>August 14, 2017</last_update_submitted>
  <last_update_submitted_qc>August 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

